Last reviewed · How we verify
Efavirenz for the first 2 weeks — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Efavirenz for the first 2 weeks (Efavirenz for the first 2 weeks) — University Hospital, Geneva.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Efavirenz for the first 2 weeks TARGET | Efavirenz for the first 2 weeks | University Hospital, Geneva | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Efavirenz for the first 2 weeks CI watch — RSS
- Efavirenz for the first 2 weeks CI watch — Atom
- Efavirenz for the first 2 weeks CI watch — JSON
- Efavirenz for the first 2 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Efavirenz for the first 2 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/efavirenz-for-the-first-2-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab